Fractyl Health

GUTS

Market cap $72.2M

Overview Fund Activity

1.02 USD

0.00

0%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.03

+0.01

0.98%

1 day

0%

5 days

10.53%

1 month

3.67%

3 months

-53%

6 months

-25%

Year to date

-52.11%

1 year

-64.34%

5 years

-92.06%

10 years

-92.06%

About: Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.

Employees: 109

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

51% more capital invested

Capital invested by funds: $29.7M [Q1] → $44.8M (+$15.1M) [Q2]

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

5.44% more ownership

Funds ownership: 50.99% [Q1] → 56.43% (+5.44%) [Q2]

6% less funds holding

Funds holding: 65 [Q1] → 61 (-4) [Q2]

18% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 22

38% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 21

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3.6

253% upside

Avg. target

$4.8

371% upside

High target

$6

488% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Ladenburg Thalmann Jeff Cohen	$3.6	Buy Initiated	28 Aug 2025
Canaccord Genuity Whitney Ijem	$6	Buy Maintained	14 Aug 2025

See Analyst Rankings

Financial journalist opinion

Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward

Fractyl Health's Revita offers a one-time procedure to maintain GLP-1 weight loss, with pivotal 45-patient trial data expected imminently. Early open-label results show Revita may significantly reduce post-GLP-1 weight regain. Despite past "OK" results in T2D, Revita's may have found its killer application in GLP-1 discontinuation patient; awarded FDA Breakthrough Device Designation.

Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Fractyl Health, Inc. (NASDAQ:GUTS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian Luque - Corporate Participant Harith Rajagopalan - Co-Founder, CEO & Director Lisa A. Davidson - CFO & Treasurer Conference Call Participants Jason Matthew Gerberry - BofA Securities, Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Whitney Glad Ijem - Canaccord Genuity Corp., Research Division William McKinnie Wood - B.

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita ® procedure sustained weight loss after GLP-1 discontinuation; incremental 6-month open-label data expected in Q4 2025 Top-line REMAIN-1 Pivotal Cohort 6-month data and PMA filing expected in H2 2026 $23M underwritten public offering expected to extend cash runway through key upcoming 3-and 6-month randomized data readouts from REMAIN-1 Midpoint Cohort Conference call today at 4:30 p.m. ET BURLINGTON, Mass.

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Offering included participation from leading institutional investors, including Nantahala Capital, ADAR1 Capital Management, Second Line Capital, 683 Capital, and SilverArc Capital Proceeds expected to extend cash runway through key upcoming 3-and 6-month REMAIN-1 Midpoint Cohort randomized data readouts from the REMAIN-1 pivotal study BURLINGTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the closing of its previously announced underwritten public offering of 21,904,761 shares of common stock and accompanying Tranche A and Tranche B warrants, including the full exercise of the underwriter's option to purchase 2,857,142 additional shares of common stock and accompanying Tranche A and Tranche B warrants, for gross proceeds of approximately $23 million, before deducting underwriting discounts, commissions, and offering expenses.

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET.

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of its underwritten public offering of 19,047,619 shares of common stock and accompanying Tranche A and Tranche B warrants, for gross proceeds of $20 million before deducting underwriting discounts, commissions, and offering expenses.

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Fractyl Health Announces Proposed Public Offering

BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering.

Fractyl Health Announces Proposed Public Offering

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related serious adverse events to date

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Fractyl Health: Speculative Buy With Binary Risk

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected in Q3 2025. Current valuation reflects financing and trial risks, but may underappreciate Revita's clinical potential as a durable alternative to GLP-1 drugs. The company's cash runway is critically short, making the REMAIN-1 midpoint data a financial survival catalyst for raising capital on favorable terms.

Fractyl Health: Speculative Buy With Binary Risk

See News Rankings

Charts implemented using Lightweight Charts™